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Abstract 7 
Rational approaches to modifying cells to make molecules of interest are of 8 
substantial economic and scientific interest. Most of these efforts are aimed at 9 
the production of native metabolites, expression of heterologous biosynthetic 10 
pathways, or protein expression. Reviews of these topics have largely focused on 11 
individual strategies or cell types, but collectively they fall under the broad 12 
umbrella of a growing field known as cell factory engineering. Here we condense 13 
>130 reviews and key studies in the art into a metareview of cell factory 14 
engineering. We identified 33 generic strategies in the field, all applicable to 15 
multiple types of cells and products, and proven successful in multiple major cell 16 
types. These apply to three major categories: Production of native metabolites 17 
and/or bioactives, heterologous expression of biosynthetic pathways, and 18 
protein expression This metareview provides general strategy guides for the 19 
broad range of applications of rational engineering of cell factories. 20 
Introduction 21 
Cells engineered for the enhanced production of native compounds, or 22 
production of heterologous products is an established and economically 23 
important discipline. Serving as the basis of all product-oriented industrial 24 
biotechnology, the economic footprint of these cell factories ranges in the 25 
hundreds of billions of US$/year on the global markets: Pharmaceutical proteins 26 
have been estimated at 140 billion US$ in 2013 (Walsh 2014); Industrial 27 
enzymes in the range of 1.8 billion US$ in 2009 (Waegeman & Soetaert 2011); 28 
Bio-derived non-protein pharmaceuticals ~100 billion US$ (Chemier et al. 29 
2009); and bulk biochemicals (excluding biofuels) 58 billion USD 30 
(Nieuwenhuizen & Lyon 2011). For comparison, the petrochemical industry is >3 31 
trillion USD/year (2015), so there is still a large market to expand into. 32 
While industrial biotechnology has a long history, it was not until the arrival of 33 
genetic engineering that it became possible to modify the DNA of the cell 34 
factories to improve production (Figure 1), a process that hitherto had been 35 
based on clonal selection. Such developments gave rise to the discipline cellular 36 
engineering (Nerem 1991), which covers both basic and applied cell research . 37 
The same year, Bailey defined metabolic engineering as a rational and directed 38 
process of engineering metabolism, rather than a cycle of trial and error (Bailey 39 
1991). Since then, the field of engineering cell factories has expanded in outlook 40 
and scope to include several "flavors" of cellular engineering specific to 41 
industrial biotechnology (Figure 1). Two examples are (i) inverse metabolic 42 
engineering (Bailey et al. 2002), in which one starts with the desired phenotype 43 
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and works towards that goal by directed genetic or environmental manipulation, 44 
and (ii) systems metabolic engineering as coined by the group of Sang-Yup Lee 45 
(Lee et al. 2007; Lee & Kim 2015) as a term for large-scale holistic metabolic 46 
engineering. However, in many applications, the engineering efforts are not 47 
limited to the metabolic network of the cell, and therefore "metabolic 48 
engineering" does not fully encompass all activities. This is particularly true for 49 
the large sector of expression of protein, native and heterologous, which covers 50 
the range from bulk enzymes to formulated pharmaceutical proteins. Here, 51 
engineering targets can be within cellular machinery such as the protein 52 
secretion pathway. To include all of these activities, this metareview defines Cell 53 
Factory Engineering, encompassing all rational approaches to improve a cell 54 
factory. 55 
The objective of this metareview is specifically not to present a comprehensive 56 
list of examples within the individual strategies, nor is it to present direct 57 
strategies for target identification, such as modeling in tandem with predictive 58 
algorithms (Ranganathan et al. 2010; Burgard et al. 2003; Pharkya & Maranas 59 
2006). For this, specialized reviews of high quality and information content 60 
already exist (See e.g. the excellent and recent work of the group of Sang Yup Lee 61 
(Lee & Kim 2015)). In this text, we will provide a meta-review summarizing 62 
several years of cell engineering efforts, in essence an applicable list of strategies 63 
generally applicable across species and products suitable for the experienced 64 
scientist. In this, we have focused on strategies applied reproducibly across 65 
multiple cell factories, and chosen the most applied microbial cell factories from 66 
the entire tree of life, spanning bacteria, yeast, filamentous fungi, and 67 
mammalian cells (in particular CHO cells), as well as some higher fungi. See also 68 
Box 1 for an overview of cell factory engineering methods in other fields. The 69 
metareview will furthermore provide representative examples of applications of 70 
the strategies for illustration. 71 
Meta-review Overview 72 
The analysis here draws on a long list of reviews supplemented by primary 73 
literature to provide an overview of cell factory engineering.  Table 1 lists the 74 
reviews cited in this text and annotations on which types of strategies and 75 
organisms these reviews are most relevant for.  76 
It is the reductionist argument of this meta-review that nearly all cell factory 77 
engineering efforts can be classified in one of the following three categories or as 78 
combinations of them: (1) optimization of the production of a metabolite in the 79 
native host; (2) production of a non-native metabolite by expression of a 80 
heterologous biosynthetic pathway; and (3) expression of a heterologous protein. 81 
Here, we condense the strategies of the reviews in Table 1 into these three 82 
generic categories, examine each in detail, and provide guidance on choosing and 83 
applying individual strategies. 84 
Production of native metabolites 85 
Native metabolites are here compounds naturally produced by the cell factory, 86 
either intracellularly or (preferably) a secreted compound. Examples are amino 87 
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and nucleic acids, antibiotics, vitamins, enzymes, bioactive compounds and 88 
proteins produced from anabolic pathways of cells (see details for protein 89 
products further below). Common for these are that they cannot be synthetically 90 
produced or for which it is not economical to do so (Stephanopoulos & Vallino 91 
1991). This has been examined for specific cells or products in a multitude of 92 
excellent reviews (see e.g. (Bailey et al. 2002; Pickens et al. 2011; 93 
Stephanopoulos & Vallino 1991; Keasling 2008; Keasling 2012; Hwang et al. 94 
2014; Wu et al. 2014; Weber et al. 2015; Kiel et al. 2010; Xiao & Zhong 2016)). 95 
Here, we will provide an overview of general strategies to increase the formation 96 
of native metabolites (Figure 2).  97 
The strategies one would apply to this problem can be reduced to ten types 98 
(Figure 2, 1A-1J). 99 
1A1-2. Pathway overexpression: Using this strategy, one would typically 100 
overexpress one or more enzymes in the biosynthetic pathway. It is a 101 
common strategy and is often achieved by overexpressing the native genes 102 
(1A1). As an alternative to normal overexpression, enzymes could be 103 
engineered to have higher activity. In either case, it can be advantageous to 104 
identify enzymatic steps with particular control of the flux to the product, 105 
such as irreversible reactions, or the first steps in the pathway. Some steps 106 
in the pathway (often the latter) may have very little control over the flux, 107 
so multiple targets should be engineered and/or metabolic control analysis 108 
(Nielsen 1998) should be employed. It has also been seen that heterologous 109 
expression of ortholog enzymes from related species (1A2) can have a 110 
larger effect than the native enzymes. The reason for this remains 111 
speculative, but one hypothesis could be a lower regulatory effect on the 112 
heterologous proteins. One example of the latter is enhanced citrate 113 
production in Aspergillus niger by heterologous expression of TCA cycle 114 
enzymes from Saccharomyces cerevisiae and Rhizopus oryzae (de Jongh & 115 
Nielsen 2008), or improved ganoderic acid accumulation in Ganoderma 116 
lucidum (Xu et al. 2012). 117 
1B1-2. Transporter engineering: Accumulation of the product in the cell can 118 
decrease the carbon flux by affecting enzyme kinetics, thus decreasing 119 
production rates and yields. Furthermore, accumulation of product can 120 
trigger feedback inhibition, which will severely limit the flux through the 121 
pathway. In some cases, the product may even be toxic. Overexpressing 122 
product efflux pumps can thus be an efficient way of increasing the flux 123 
(1B1) (Dunlop et al. 2011; Wu et al. 2014; Lee et al. 2012; Lee & Kim 2015). 124 
One example is the improved production of biofuels in Escherichia coli by 125 
systems engineering of 43 efflux pumps (Dunlop et al. 2011). This strategy 126 
both increased production and lowered product toxicity. Alternatively, or 127 
in combination with 1B1, gene knock-outs of uptake transporters specific 128 
for the product (1B2) can also be effective (Lee et al. 2012).  129 
1C.  De-branching: Branching or competing pathways can decrease the overall 130 
flux towards the product (Pickens et al. 2011; Lee et al. 2012; Pfleger et al. 131 
2015). If these pathways are not lethal, deleting the first branching step 132 
may improve product formation. With essential pathways, decreasing the 133 
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activity by knock-down or e.g. tunable promoters can be an alternative 134 
option. This is a common strategy; one comprehensive example includes 135 
the knock-out of L-lysine, L-methionine, and L-glycine biosynthesis for 136 
improved isoleucine production in E. coli (Park et al. 2012). 137 
1D.  Product degradation: Any non-essential reactions which converts the 138 
product to unwanted metabolites, should be deleted, as these may degrade 139 
the product and decrease yields and titers. Such an example is the work of 140 
Lee et al, where threonine dehydrogenase was deleted in E. coli to increase 141 
the production of L-threonine (Lee et al. 2007).  142 
1E1-3. Co-factor engineering: In some cases, it has been shown that a major 143 
limitation is the availability of co-factors (NADH/NAD+, NADPH2, NADP+, 144 
Ac-CoA, etc) (Lee & Kim 2015; Ghosh et al. 2011; Lee et al. 2012; Pfleger et 145 
al. 2015; van Rossum et al. 2016). In these cases, one must make more co-146 
factors available by engineering other pathways. Ideally, the deletion of a 147 
non-essential enzyme, which catabolizes large amounts of the co-factor, is 148 
preferred (1E1). In cases where this is not possible, an alternative might be 149 
replacing such an enzyme with a native or heterologous enzyme with the 150 
same function, but specific for another co-factor (1E2). An example of this is 151 
substitution of a native NADPH-dependent glutamate dehydrogenase with 152 
an over-expressed NADH-dependent glutamate dehydrogenase to enhance 153 
sesquiterpene production in S. cerevisiae (Asadollahi et al. 2009). A third 154 
option is the insertion (Yamauchi et al. 2014) or overexpression (Cui et al. 155 
2014) of an E. coli transhydrogenase for interconversion of NADH and 156 
NAPDH (1E3). 157 
1F.  Removal of feedback inhibition: In many cases, especially with products 158 
that are a part of standard growth metabolism (e.g. amino acids), strong 159 
feedback inhibition exists to tightly regulate the concentrations of the 160 
product. When one wishes to produce such compounds in large amounts, it 161 
can be necessary to disable feedback inhibition. Often this is achieved by 162 
random or targeted mutagenesis of enzymes in the pathway known to be 163 
feedback inhibited (Lee & Kim 2015). In some cases, analogs of the product, 164 
which binds tightly/near irreversibly to the regulated enzymes, can be 165 
used to screen for feedback deregulated mutants. This has been used e.g. 166 
for L-threonine (Lee et al. 2003), and L-tryptophan and L-serine (Rodrigues 167 
et al. 2013), both in E. coli. This strategy was also efficient for engineering 168 
acid production in A. niger (de Jongh & Nielsen 2008) and for production of 169 
fatty acids in E. coli (Pfleger et al. 2015). 170 
1G.  By-product elimination: Several species produce varying amounts of 171 
byproducts. Often these byproducts – while not directly linked to the 172 
metabolic pathway of the product – compete with the product for available 173 
carbon and/or co-factors (Lee et al. 2012). If possible without making 174 
lethal deletions, the enzymatic activities producing such compounds should 175 
be deleted or reduced. Numerous successful examples of this strategy can 176 
be found, for instance removal of glycerol biosynthesis in S. cerevisiae for 177 
increased ethanol-production (Wang et al. 2013). 178 
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1H.  Precursor/substrate enrichment: It will often be advantageous to 179 
increase the availability of the substrate for the product biosynthesis (Lee 180 
& Kim 2015; Pickens et al. 2011; Lee et al. 2012). This can be achieved by a 181 
multitude of strategies, essentially by considering the substrate as an 182 
intermediate product, and applying one or more of strategies 1A-1J to 183 
increase substrate formation. When considering substrates, one should also 184 
remember to take co-substrates such as acetyl-CoA in account (See e.g. a 185 
recent review of Ac-CoA engineering in S. cerevisiae (Nielsen 2014)).  Other 186 
carbon donors can also become limiting, e.g. malonyl-CoA and glucose-1-187 
phosphate in the production of an anti-cancer compound in Streptomyces 188 
argillaceus (Zabala et al. 2013).  189 
1I.  De-regulation of carbon catabolism: In some cases, the pathway of 190 
interest may be subject to general metabolic regulation of the cell e.g. 191 
general regulators of carbon catabolism or nitrogen source induced 192 
regulation. Examples of this is de-regulation of galactose metabolism in S. 193 
cerevisiae by deletion of negative regulators, leading to derepression and 194 
increased galactose utilization (Ostergaard et al. 2000) or disruption of a 195 
global regulator in Pichia guilliermondii to trigger aerobic glucose 196 
catabolism for ethanol production (Qi et al. 2014). 197 
1J. Signal transduction engineering: In some cases, the production of 198 
specific metabolites is not regulated by carbon or nitrogen sources (1I), but 199 
may be subject to signals from e.g. micronutrients, or from other steps in 200 
the pathway. In these cases, engineering signal transduction can be a strong 201 
strategy (Kiel et al. 2010).  202 
Choosing a strategy for producing native metabolites 203 
Generally, there is a logical order in which to apply strategies 1A-1J. The 204 
strategies can be sorted into three categories, which we suggest to apply in 205 
progression. 206 
Step 1: Direct optimization of the pathway in any way possible. The main goal of 207 
this step is to ensure that neither enzymes nor intermediates of the pathway are 208 
limiting production. If this is not achieved, the other strategies may not be 209 
effective. This can be addressed by the following actions in roughly this order: 210 
i. Overexpression of the biosynthetic pathway using the strategies of 1A. This 211 
ensures that the concentrations of the enzymes are not limiting. 212 
ii. Enrichment for the substrates (1H) and for the co-factors (1E), thus ensuring 213 
that the required metabolites, precursors and co-factors do not become 214 
limiting. 215 
iii. Ensuring that the product is removed from the cell by transporter 216 
engineering (1B) if possible. Accumulation of the product can seriously 217 
decrease product formation as enzyme kinetics are dependent on 218 
concentrations of the product. Furthermore, product accumulation can in 219 
some cases lead to feedback inhibition of the entire pathway. 220 
iv. If feedback inhibition is known for the pathway, this should be engineered 221 
out if possible, or removed by mutagenesis, screening and reverse genetics 222 
(1F). Again, this may not be a problem if actions i–iii are limiting. 223 
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Step 2: Remove competing activities. Once the pathway itself is optimized, the 224 
next steps is to ensure that no other pathways are impairing the product 225 
formation, either directly by sharing metabolites or co-factors, or by using 226 
carbon which could be converted to product. The three main strategies here are 227 
as follows: 228 
i. De-branching (1C). Any pathways that share intermediates or pre-cursors 229 
with the pathway of interest should be deleted if possible. 230 
ii. Product degradation (1D). A particular case of 1C is pathways 231 
converting/degrading the product of interest. These should also be deleted if 232 
possible. 233 
iii. Removal of by-products (1G). While by-products are not often directly 234 
associated with the product pathway, by-products will use carbon, cofactors, 235 
and energy which could be converted into product. 236 
Step 3: Application of global regulation engineering. This does not seem to be 237 
common strategies, as it will often be highly effective to perform the actions 238 
above. However, should this be in place, engineering carbon repression (1I) or 239 
similar signal transduction pathways (1J) can be a final approach. 240 
Clearly, the actions above can - and should - be combined for increased effects. 241 
Prime examples of this are large-scale rational design of metabolic pathways, 242 
which has been applied to great effect several systems, in particular bacterial 243 
hosts (Lee et al. 2007; Rodrigues et al. 2013; Becker et al. 2013) and yeast (Wu et 244 
al. 2014; Lee et al. 2012). 245 
Heterologous expression of biosynthetic pathways 246 
When trying to produce an interesting compound, one of the most important 247 
decisions is the choice of production in the native host, and optimize this host, or 248 
transfer of the pathway to another well-known host. If the original host can be 249 
adapted to an industrial fermentation process, and there are no health-related 250 
risks in doing so (e.g. production of toxic byproducts), this can be a preferred 251 
strategy (as was the case e.g. for penicillin). However, in many modern cases, the 252 
potential of using an industrially preferred cell factory and related platform 253 
processes out-weighs the difficulty of transferring the pathway. In some cases, 254 
transplanting a pathway also removes metabolic inhibition found in the original 255 
host (Martin et al. 2003). 256 
In this section we will examine how one may need to adapt the cell factory in 257 
order to accommodate production of a heterologous product. In general, several 258 
excellent specialized reviews exist within this area, and for additional details on 259 
specific cases for particular groups of compounds, we recommend these for 260 
further studies (See e.g. (Pickens et al. 2011; Pfeifer & Khosla 2001; Lee et al. 261 
2012; Xiao & Zhong 2016)). Here, we give an overview of common and general 262 
problems regarding heterologous expression of pathways. 263 
Innate differences between the native host and the cell factory of choice are major challenges in 264 
expressing a pathway in a new host. In general, the compatibility of the enzymes and metabolites 265 
with the new host should be considered. The more complicated the pathway, the larger the 266 
advantage of choosing a more closely related host. Major types of challenges are shown in 267 
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Figure 3.  269 
These challenges can be condensed into points 2A-2F below. Note that these 270 
cover both eukaryotic and prokaryotic hosts and donors in combination, 271 
meaning that some of these are specific to certain types of cells (e.g. intracellular 272 
compartmentalization is seldom a problem in prokaryotes). 273 
2A.  Compartmentalization or steric proximity: In heterologous expression, 274 
a common pitfall is not making sure that the pathway is expressed in the 275 
same compartment as the substrate metabolite. If the heterologous 276 
enzymes do not contain targeting signals, in a eukaryotic host, they will be 277 
expressed in the cytosol. In case the substrate is in another compartment, 278 
targeting sequences or gene fusions can be applied to direct the 279 
heterologous enzyme(s) to the correct compartment (Siddiqui et al. 2012). 280 
As an alternative, synthetic scaffolds have been made to bring biosynthetic 281 
enzymes together with great effect both in E. coli (Dueber et al. 2009) and S. 282 
cerevisiae (Wang & Yu 2012). 283 
2B1-2. Co-factor availability: Any overexpressed pathway will present a 284 
significant drain on available co-factors (van Rossum et al. 2016). It is 285 
advantageous to ensure that these are present in sufficient amounts in the 286 
host (2B1), as shown e.g. in Streptomyces coelicolor (Borodina et al. 2008). 287 
This may be specific to the compartment (2B2). Alternatively, 288 
transhydrogenases may be engineered as described in 1E1-2. 289 
2C1-2. Substrate and co-substrate availability: In addition to co-factors, one 290 
must also ensure that the host produces all substrates and co-291 
substrates/precursors required for the pathway (2C1). It may also be the 292 
case that the host produces similar compounds, which may be competing 293 
for the substrate or precursors. In these cases, it can be advantageous to 294 
delete the competing pathways (Baltz 2016). It has been demonstrated in 295 
e.g. E. coli (Rodrigues et al. 2013; Rodrigues et al. 2014) and 296 
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Corynebacterium glutamicum (Becker et al. 2013) that high availability of 297 
the substrate in the heterologous host improves productivity. If all (co-298 
)substrates are not available or present in low amount, it is necessary to 299 
insert or overexpress biosynthetic genes for these as well (2C2), Examples 300 
of this are seen for e.g. amino acids or oxaloacetate (Kind et al. 2010; 301 
Rodrigues et al. 2013) or adipic acid (Yu et al. 2014).  302 
2D1-2. Product efflux pumps: When adding biosynthesis of a new compound to 303 
a cell, specific transporters for that compound may not exist. Accumulation 304 
of the product in the cell will decrease the flux through the biosynthetic 305 
pathway (Lee et al. 2012) and may also have toxic effects on the cell 306 
(Pfeifer & Khosla 2001). Passive transport or unspecific transporters may 307 
be available, but if this is not the case, a specific transporter must be added 308 
(2D1) as seen for e.g. flavonoids (Wu et al. 2014) or cadaverine (Qian et al. 309 
2011). Should the pathway be compartmentalized, this also needs to be 310 
accounted for, possibly by expressing an organelle-specific transporter 311 
(2D2), e.g. with mitochondrial products (Chen et al. 2015). 312 
2E. Biosynthesis of functional groups. For a number of proteins, all functional 313 
groups are not encoded by the gene, but require separate biosynthesis. One 314 
example is heme groups, found in multiple types of enzymes requiring 315 
oxygen as a co-factor. Heme groups are not found in all prokaryotes 316 
(Cavallaro et al. 2008), and may be limiting in some fungal systems 317 
(Franken et al. 2011). Another functional group is Fe-S clusters, which have 318 
several different biosynthetic pathways specific to the type of host 319 
organism. Fe-S clusters are synthesized in the cytoplasm of bacteria and in 320 
the mitochondrion of eukaryotic microbes, from where they are 321 
transported into the cytosol. In order for the heterologous pathway to be 322 
functional, it may be required to express the native biosynthesis pathway 323 
heterologously (2E). A specific type of Fe-S proteins (ferredoxins) mediate 324 
electron transfer. Cases exist where the expression of specific ferredoxins 325 
from the native host were necessary for optimal expression of the pathway 326 
(Molnár et al. 2006). 327 
2F. Transcription engineering. With many secondary metabolites, several 328 
genes are required to act in concert to form the product. If only one or a 329 
few genes are active, the product may be absent or different from the 330 
expected product. For many of these pathways, one regulatory protein 331 
exists, which transcriptionally activates the entire pathway. If one uses 332 
native promoters to express the genes, it can be advantageous to 333 
overexpress the regulatory protein (if it can be identified), and thereby 334 
induce the entire set of genes (Pickens et al. 2011; Baltz 2016; Bekiesch et 335 
al. 2016). Examples of this include the transplant of the geodin gene cluster 336 
from A. terreus into A. nidulans and substitution of the native promoter for 337 
the transcription factor for a strong constitutive promoter, thus allowing 338 
heterologous expression of geodin (Nielsen et al. 2013). 339 
Choosing a strategy for heterologous pathway expression 340 
For heterologous pathways, the strategy is a combination of the issues 341 
encountered in the expression of native pathways, and issues arriving from 342 
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interaction with the new host. Roughly, the considerations can be sorted into two 343 
major steps: 344 
Step 1: Compatibility of the pathway to the host. The actions listed in this step are 345 
interesting in that they may not be needed, dependent on the interaction with 346 
the host. Appropriate host selection can thus be used already in the design fase 347 
to remove or minimize the problems (For a few reviews on host selection, see e.g. 348 
(Fisher et al. 2014; Lee & Kim 2015; Bekiesch et al. 2016)). However, if these are 349 
not considered, no other engineering strategies may be effective. The three main 350 
things to consider are thus: 351 
i. Compartmentalization (2A). Spatial co-localization of the inserted enzymes 352 
as well as availability of co-factors and precursors in the compartment(s) of 353 
choice. 354 
ii. Functional group biosynthesis (2E). Ensuring functionality of all enzymes. 355 
iii. Substrates, co-substrates (2C), and co-factors (2B). Ensuring that all required 356 
precursors are available in the host. 357 
Step 2: Optimization of the pathway. Once it is ensured that the pathway is 358 
functional in the host, one can apply strategies to increase flux through the 359 
pathway. Here the following five steps should be investigated, sorted in order of 360 
perceived importance. 361 
i. Application of transcription engineering where possible (2B). Increased 362 
transcription of all enzymatic steps is an efficient way to increase enzyme 363 
levels. 364 
ii. Pathway overexpression strategies (1A1) and removal of feedback inhibition 365 
(1F) are equally applicable to heterologous pathways. 366 
iii. Removal of competing activities as described in 1C and 1D. This is 367 
particularly interesting when producing a compound, where the host 368 
produces several similar compounds competing for the precursors, e.g. 369 
within microbial bioactive compounds (Pickens et al. 2011). 370 
iv. Improving the product efflux by transporter engineering (2D and 1B). 371 
v. Removal of by-products (1G) can possibly be considered last, as the 372 
strategies above are more direct towards improving the pathway. However, 373 
by-products removal has been seen to have importance here (Wu et al. 2014; 374 
Pickens et al. 2011). 375 
In summary, the overview above provides a strategy guide for heterologous 376 
pathway expression encompassing many different reviews and studies. However, 377 
it is important to note, that this does not cover host-specific or donor-specific 378 
problems. In these cases, we direct the reader to Table 1 to find suggestions for 379 
additional species-specific engineering challenges. 380 
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Protein expression 381 
The expression of proteins, both homologous and heterologous, is presently 382 
done in a wide variety of hosts from E. coli and Bacillis subtilis, over yeasts, e.g. 383 
Klyuveromyces lactis, Pichia pastoris and S. cerevisiae, through filamentous fungi 384 
such as A. niger, to cells derived from multicellular organisms such as mammals 385 
and insects. The variety of proteins of commercial interest is great, ranging from 386 
bulk enzymes to complex biopharmaceuticals (Association of Manufacturers and 387 
Formulators of Enzyme Products 2009; Walsh 2014). 388 
Due to the diverse properties of proteins, it is currently not possible to use one 389 
platform organism for expression of all proteins. The scientist must thus choose 390 
the cell factory based on the properties and applications of the desired protein. 391 
The advantages and disadvantages of applying different cell factories are 392 
discussed in several excellent reviews specialized to particular expression 393 
systems (See Table 1). In particular we recommend the review of (Waegeman & 394 
Soetaert 2011) for an very clear comparison of expression systems in addition to 395 
a thorough overview of E. coli expression. 396 
Despite the variety of employed systems, there are generic strategies applicable 397 
to high-yield expression of proteins. Not all of the strategies presented here are 398 
applicable in every host, but we focus on strategies, which are applicable in 399 
several hosts. For this reason, the present review does not discuss strategies 400 
related to the accumulation of protein in inclusion bodies, a feature encountered 401 
in some bacterial hosts such as E. coli for some proteins with particular folding. 402 
For this, we again direct the reader to specialized overviews (de Marco 2009; 403 
Waegeman & Soetaert 2011). 404 
Overall, the successful high-yield process for production of a given protein requires high 405 
transcription and translation of the gene, successful targeting of the protein to the secretion 406 
pathway (if secretion is desired), correct folding and limited induction of secretion stress, the 407 
desired post-translational modifications (PTMs), efficient secretion, and limited or no degradation 408 
of the product in the medium. In general, the major strategies for engineering increased protein 409 
expression can be found in 410 
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Figure 4, and are summarized in points 3A-3F below: 412 
3A1-2. Promoter engineering: Nearly all systems aim at ensuring maximal 413 
availability of recombinant mRNA so that this is not a bottle neck for 414 
protein expression. The major strategy employed is addition of a highly 415 
expressed constitutive promoter (3A1). A selection of these are known for 416 
most hosts such as the native GAPDH-promoter in yeasts (Mattanovich et al. 417 
2012), the heterologous gdhA promoter in Aspergillus species (Fleissner & 418 
Dersch 2010), or viral promoters in mammalian hosts (Wurm 2004). It is 419 
also a common strategy to develop synthetic promoters (Dehli et al. 2012; 420 
Vogl et al. 2013; Fleissner & Dersch 2010). Alternatively, one can employ 421 
strong inducible promoters (3A2) to have a bi-phasic process (Waegeman 422 
& Soetaert 2011; Fleissner & Dersch 2010), for instance methanol-423 
inducible gene expression in the methylotrophic yeast P. pastoris 424 
(Mattanovich et al. 2012; Damasceno et al. 2012). Reviews with particularly 425 
good overviews of promoters for specific systems are available (Celik & 426 
Calık 2011; Fleissner & Dersch 2010). A complementary strategy to the use 427 
of strong promoters is the expression from high-copy plasmids (Rosano & 428 
Ceccarelli 2014), or multigene insertions (Westwood et al. 2010; Wurm 429 
2004; Damasceno et al. 2012). Other transcriptional elements such as 430 
enhancers, transcription factor binding, and chromosomal elements should 431 
be considered dependent on expression systems (Liu et al. 2013; Fleissner 432 
& Dersch 2010; Westwood et al. 2010). 433 
3B1-2. Gene fusion for enhanced secretion: For proteins with no inherent 434 
secretion signal, the gene sequence requires engineering to facilitate 435 
secretion of the protein. The predominant way is the addition of a signal 436 
peptide/secretion leader signal (3B1). This can also be applied to substitute 437 
the original signal peptide for improved secretion in the host. For the major 438 
hosts, efficient signal peptides are known from native secreted proteins, e.g. 439 
alpha-mating factor or acid phosphatase in yeasts (Mattanovich et al. 2012; 440 
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Damasceno et al. 2012) or leader sequences from secreted proteins in 441 
Aspergillus (Fleissner & Dersch 2010) or bacteria (Liu et al. 2013). In some 442 
combinations of host and protein, this may not be sufficient; in which case, 443 
the gene of interest is fused with the sequence for a carrier protein (3B2), 444 
which then has the effect of ushering the protein out of the cell. One 445 
example is the production of animal proteins in Aspergillus species, where a 446 
successful strategy for bovine chymosin production was fusion with the 447 
glucoamylase gene. This approach has since then become a preferred 448 
method (Ward et al. 1990; Ward 2011; Fleissner & Dersch 2010). 449 
3C. Stability of heterologous gene transcripts: Most eukaryotic genes contain 450 
introns. In many cases, their removal from the transcript is necessary to 451 
generate a functional gene product due to differences in (or absence of) 452 
splicing machinery between species (Hamann & Lange 2006; Innis et al. 453 
1985). In higher eukaryotic systems a single intron early in the transcript 454 
or in the promoter can however successfully enhance stability of mRNA 455 
and increase the final product titer (Borkovich et al. 2004). In many cases, 456 
codon optimization of heterologous transcripts are often needed due to 457 
incompatibility between the host and the protein codons, e.g. use of rare 458 
codons or difference in stop codons. In general, the half-life of a 459 
heterologous transcript might be different from related transcripts of the 460 
host. In bacterial system, the importance of terminators and 3'UTR regions 461 
to transcript stability has been well established (Cambray et al. 2013; 462 
Pfleger et al. 2006; Curran et al. 2013). Often changing natural or adding 463 
new structures, e.g. hairpin structures, to the ends of transcripts, have been 464 
shown in bacteria to accumulate mRNA and increase product formation 465 
(Hienonen et al. 2007). In yeast and fungal systems, recent studies show 466 
that changing a terminator can effectively optimize the transcript stability 467 
and increase the product titer (Curran et al. 2013).  468 
3D1-2. Improved translocation to the ER: The induced pressure on the 469 
secretion machinery creates numerous rate-limiting steps. The first is 470 
already at the entrance of the secretion pathway, through translocation 471 
(3D1). A successful approach for several systems is overexpression of 472 
signal peptidases cleaving the signal peptide by entrance to the ER (Meta et 473 
al. 2009; Dijl et al. 1991; Ailor et al. 1999). Insufficient amount of 474 
proteolytic cleavage enzymes may also be limiting for secreted proteins 475 
with pre-cursor domains (3D2). An example is for therapeutic protein 476 
produced in CHO cells, where overexpression of the cleaving enzyme PACE, 477 
increase the secretion capability for several different proteins 478 
(Sathyamurthy et al. 2012). 479 
3E1-2. Protein secretion stress engineering: It is generally found that 480 
overexpression of proteins induces protein secretion stress to some degree, 481 
which decreases productivity and overall cell fitness (Lubertozzi & 482 
Keasling 2009; Gasser et al. 2008; Schröder 2008). One generally applied 483 
strategy is the overexpression of chaperones (3E1). This strategy has been 484 
proven to be successful in several studies in a multitude of systems: E. coli 485 
(Waegeman & Soetaert 2011; Gasser et al. 2008; Rosano & Ceccarelli 2014), 486 
other bacteria (Gasser et al. 2008), yeasts (Mattanovich et al. 2012; Gasser 487 
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et al. 2008), fungi (Ward 2011; Fleissner & Dersch 2010), and CHO cells 488 
(Ailor & Betenbaugh 1998; Jossé et al. 2012; Pybus et al. 2013). It has also 489 
been broadly successful to regulate global activators of the ER or the 490 
unfolded protein response (3E2), in bacteria (Gasser et al. 2008), S. 491 
cerevisiae (Valkonen, Penttilä, et al. 2003; Mattanovich et al. 2012; Calfon et 492 
al. 2002), in A. niger var. awamori (Valkonen, Ward, et al. 2003; Carvalho et 493 
al. 2012; Fleissner & Dersch 2010) and in mammalian cells (Ohya et al. 494 
2008; Tigges & Fussenegger 2006; Ku et al. 2008).  495 
3F. Engineering the post-translational modification machinery: In some 496 
cases, the bottlenecks are in the formation of disulfide bridges (Schröder 497 
2008). This has been a problem in E. coli in particular (de Marco 2009), but 498 
proteins involved in disulfide bridge formation have been seen to be 499 
limiting in many cases, as seen by the positive effect of protein disulfide 500 
isomerase (PDI) in many other organisms, such as several yeasts, 501 
Aspergillus (Gasser et al. 2008; Fleissner & Dersch 2010) and CHO (Borth et 502 
al. 2005; Davis et al. 2000; Mohan et al. 2007).  503 
3G. Improved vesicle trafficking. Another rate-limiting step is the vesicle 504 
trafficking between ER-Golgi and Golgi-membrane. Overexpression of 505 
SNAREs and their key regulators can stimulates vesicular trafficking in 506 
yeast and enhance heterologous protein secretion (Hou et al. 2012; 507 
Ruohonen et al. 1997). Vacuolar protein sorting is complex, illustrated by 508 
disruption of the vacuolar protein sorting receptor, Vsp10p, which has a 509 
positive impact on secreted protein in both filamentous fungi and yeast 510 
(Yoon et al. 2010; Idiris et al. 2010). 511 
3H. Protein glycosylation engineering. This discipline does not directly aim to 512 
improve to production rate or titer of the product, but instead addresses 513 
protein quality, in the form of protein glycosylation. This has two branches, 514 
one where it is sought to optimize the native protein glycosylation, and one 515 
where the host organism does not have the required protein glycosylation 516 
features, and these are engineered into the cell factory (Mattanovich et al. 517 
2012; Hossler 2012; Hossler et al. 2009; Andersen et al. 2011; Vogl et al. 518 
2013). E. coli, like most prokaryotes, does not have native protein 519 
glycosylation, but genes from other prokaryotes with protein glycosylation 520 
have successfully been engineered into the host (Waegeman & Soetaert 521 
2011). Protein glycosylation has also been engineered in filamentous fungi 522 
(Ward 2011). A very ambitious example is the expression of major parts of 523 
the human glycosylation pathway in P. pastoris (Li et al. 2006; Hamilton et 524 
al. 2006; Choi et al. 2003; Damasceno et al. 2012), a technology later 525 
acquired by Merck Inc. (Walsh 2010). 526 
3I. Protease deletions: The deletion of extracellular proteases has been 527 
pursued in many systems with significant effects (Ward 2011; Fleissner & 528 
Dersch 2010). Examples include the deletion of all 25 known proteases in E. 529 
coli (Meerman & Georgiou 1994), S. cerevisiae (Tyo et al. 2014), and the 530 
deletion of five proteases in A. oryzae (Jin et al. 2007). Another strategy, 531 
with effects in several Aspergillus species, has been the identification and 532 
deletion of a global regulator of protease expression, PrtT. Deletion of this 533 
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gene eliminates nearly all protease activity (Punt et al. 2008; Fleissner & 534 
Dersch 2010).  535 
3J. By-product removal: A final general strategy, in all species, is the removal of 536 
byproducts with negative effect on protein production. Examples include 537 
removal of acetate biosynthesis in E. coli (Waegeman & Soetaert 2011), 538 
oxalic acid production in Aspergilli (Li et al. 2013), or lactate production in 539 
CHO cells (Kim & Lee 2007). All of these have been shown to improve 540 
product formation, growth characteristics or both. 541 
Choosing a strategy for protein expression 542 
Contrary to the strategies for production of smaller compounds, where the yield 543 
and titer of the product is the primary optimization criterion, it is more difficult 544 
to define a generalized order of engineering strategies for protein products. The 545 
main reason is, that for some proteins – in particular pharmaceuticals – quality is 546 
more important than quantity. In some cases, quantity even has a detrimental 547 
effect on quality, as it may elicit stress responses in the cell which degrades the 548 
product (Wurm 2004; Damasceno et al. 2012; Hossler 2012; Hossler et al. 2009). 549 
Therefore, we propose two strategies, one for optimizing titers (e.g. for enzymes 550 
and bulk products), and one for products focused on quality (i.e. 551 
pharmaceuticals): 552 
Strategy A: Optimal expression of the heterologous gene. Here, multiple initiatives 553 
can be used separately, sequentially or in parallel, to find the strategy that is the 554 
most efficient. The following six actions are thus applicable only in the cases 555 
where that factor is limiting. In general, actions 3A-3C in particular are relatively 556 
consistently applied in successful studies. 557 
i. Selection and engineering of optimal promoters (3A) are vital for high levels 558 
of transcript, so this does not become a limiting factor. 559 
ii. Engineering of the heterologous gene in regard to codon compatibility and 560 
optimality and removal or adaptation of introns (3C) are also found in nearly 561 
all studies. 562 
iii. Selection and/or engineering of the secretion signal (3B) is required to 563 
ensure secretion of the product, and appropriate trafficking of the peptide 564 
chain to the ER. This can affect the production by several fold. 565 
iv. Protein secretion stress reduction (3E), in particular regarding the formation 566 
of di-sulfide bridges, generally increases product formation. 567 
v. Similar to as is seen for small molecules (1D), removal of product 568 
degradation improves productivity. For proteins, this is solved by protease 569 
deletions (3I). 570 
vi. Finally, it has been shown that engineering vesicle trafficking (3G) and 571 
translocation to the ER (3D) increases productivity. However, it is quite few 572 
cases, possibly due to the complexity of engineering these processes. It thus 573 
becomes difficult to evaluate how applicable this is in general. 574 
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Strategy B: Protein quality. For optimization of protein quality, the strategy 575 
depends on which quality criterion is suboptimal in the production process, and 576 
a first step should thus be the determination of this. Here, analytical 577 
biochemistry will be the primary tool, and thus not within the scope of this 578 
metareview. Once it has been established, one can apply one or more of the 579 
following four engineering types: 580 
 Protein glycosylation engineering (3H) is generally very attractive for 581 
glycosylated biopharmaceuticals(Walsh 2014; Ratner 2014). 582 
 Engineering di-sulfide bridge formation (3F) and protein folding (3E) in 583 
general can help remove erroneously folded protein and decrease protein 584 
folding-associated stress. 585 
 Protease deletions (3I) are just as important for maintaining protein quality 586 
as quantity.  587 
In addition to the strategies of this section, one can also consider adding 588 
strategies of the previous sections where appropriate. In particular by-product 589 
removal (3J) has been demonstrated to be efficient. 590 
Conclusions 591 
Considering the breadth and depth of the strategies discussed above, it is clear 592 
that the field of cell factory engineering as a whole has come a long way. Through 593 
tens of thousands of studies, a multitude of individual challenges have been 594 
solved across a broad range of expression systems and diverse types of 595 
compounds. New and interesting avenues are being opened, such as expansion of 596 
the substrate range of E. coli turning it into a synthetic methylotroph (Müller et 597 
al. 2015), or achieving the biosynthesis of caffeine and other methylxanthines in 598 
yeast from plant biosynthetic genes (McKeague et al. 2016), or achieving 599 
biobased nylon through large-scale engineering in C. glutamicum (Kind et al. 600 
2014). We are also now seeing engineering of central metabolism for increased 601 
protein production (Nocon et al. 2014). It seems like there is no obvious limit to 602 
the possibilities in sight. 603 
Furthermore, increasingly advanced work is being published, opening the field 604 
up into the applications of synthetic biology. This impacts small parts of the cell 605 
factory engineering, such as the improvements in synthetic promoters (Vogl et al. 606 
2013), and at larger scale such as building artificial pathways rather than using 607 
“simple” heterologous expression. Examples here include the biosynthesis of 608 
gastrodin (Bai et al. 2016), and the impressive feat of the Smolke lab to 609 
biosynthesize opiods in S. cerevisiae (Thodey et al. 2014; Galanie et al. 2015).  610 
Another interesting development is the use of engineered consortia of species for 611 
achieving particular activites and synergies from using multiple species. A recent 612 
example employs bacterial consortia for desulfurisation of oil-based fuels 613 
(Martínez et al. 2016), thus improving the quality. 614 
Even so, there are still significant problems, which need to be addressed. Despite 615 
the extensive size of the toolbox of strategies outlined above, it is still difficult to 616 
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know a priori which modifications are required for a specific combination of 617 
product and cell factory. This is one of the main reasons why the development 618 
time for new cell factories remains the largest bottleneck for new bioproducts. 619 
In order to move the field forward, these challenges must be addressed in 620 
multiple ways. Currently we see a next major step to predict how cells change 621 
dynamically over the course of cultivation. At the moment, the most successful 622 
modeling of biological systems has been for steady state; which is often not 623 
representative of the conditions in a bioreactor in a long production process. 624 
Another brick in the wall will be the new conceptual frameworks (e.g. systems 625 
biology or system metabolic engineering), which are moving towards holistic 626 
design of cell factories and biological networks (Nocon et al. 2014). 627 
To achieve these goals, the importance of efficient genetic engineering and 628 
genome editing tools cannot be overstated. Every time genetic engineering 629 
technologies have improved, so has the sophistication of cell factory engineering. 630 
Synthetic biology and genome editing technologies such as CRISPR will 631 
accelerate cell factory engineering as we know it(Jakočiūnas et al. 2016), and 632 
they also promise to facilitate more-rapid tests of new theories, permutations of 633 
solutions, and generally cell engineering at a systems level.  634 
In tandem, dynamic modeling, holistic design, synthetic biology, and genome 635 
editing hold great promises for rational design of biological systems. 636 
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Box 1. Research applications of cell factory engineering 648 
The focus of the current review is on cell factory engineering for biotechnological 649 
applications. However, there are many other applications of cell factory 650 
engineering in life sciences and medicine.  651 
Besides industrial applications, a main application of cell factory engineering is 652 
to study the biological function of genes and proteins in basic research. For this, 653 
genome engineering and synthetic biology tools can be applied to regulate and 654 
remove current gene function or introduce new followed by analyzing the effect 655 
on cellular functions including biochemical reactions, regulatory networks or cell 656 
phenotypes (Hsu et al. 2014; Bashor et al. 2010). An example is engineering of 657 
genes involved in glycosylation to study their function in generating certain 658 
glycoforms that can be applied to achieve homogenized glycoforms on 659 
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recombinant proteins for comparative studies of their biological effect (Yang et 660 
al. 2015).  661 
Cell factory engineering is also highly applied in generating reagents for research. 662 
Examples includes expression of antibodies to obtain reagents for genetics 663 
studies (Barnstable et al. 1978), hormones to obtain reagents for immunoassays 664 
(Ribela et al. 1996), and purified proteins for structural analysis by 665 
crystallographers and NMR spectroscopists (Edwards et al. 2000). In addition, 666 
the produced products from cell factory engineering can be applied in screening 667 
for drug activity or as potential drug target for medical applications (Trosset & 668 
Carbonell 2015). This also includes engineering of natural probiotics to produce 669 
valuable compounds for enhancement of their benefit to the host (Behnsen et al. 670 
2013). 671 
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Table 1 – Overview of reviews covered in this text. Stars on the right denote the general relevance of the 1179 
text for cell factory engineering  1180 
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Protein expression Biopharma * 
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Soetaert 2011) 
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cerevisiae 
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(Hwang et al. 2014) Streptomyces sp. Native PWs Bioactives ** 
(Wu et al. 2014) E. coli, S. 
cerevisiae 
Heterologous PWs Flavenoids ** 
(Anyaogu & 
Mortensen 2015) 
Fungi Heterologous PWs Bioactives * 
(Xiao & Zhong 
2016) 
Basidiomycetes Heterologous PWs Terpenoids * 
(Nielsen 1998) Bac, Yeasts, 
Fungi, Mam 
All Any ** 
(van Rossum et al. 
2016) 
S. cerevisiae Native and 
heterologous PWs 
Ac-CoA-derived 
compounds 
** 
(Lee et al. 2012) E. coli Native and 
heterologous PWs 
Small molecules *** 
(Nielsen 2014) S. cerevisiae Native and 
heterologous PWs 
Ac-CoA-derived 
compounds 
* 
 (Pfleger et al. 2015) E. coli, S. 
cerevisiae 
Native and 
heterologous PWs 
Oleochemicals ** 
(Pfeifer & Khosla 
2001) 
S. coelicolor, E. 
coli, Yeasts, Fungi 
Native and 
heterologous PWs 
Polyketides ** 
(Siddiqui et al. 
2012) 
Yeasts Heterologous PWs Bioactives *** 
(Franken et al. 
2011) 
Fungi Heterologous PWs Heme * 
(Baltz 2016) Actinomycetes Heterologous PWs Bioactives ** 
(Bekiesch et al. 
2016) 
Actinomycetes Heterologous PWs Bioactives * 
(Fisher et al. 2014) Bac, Yeasts, Fungi Heterologous PWs Any ** 
30 
(Mattanovich et al. 
2012) 
Yeasts Protein expression Biopharma, Enzymes ** 
(Hossler 2012; 
Hossler et al. 2009) 
Mam Protein expression Biopharma ** 
(Andersen et al. 
2011) 
Mam Protein expression Biopharma ** 
(Damasceno et al. 
2012) 
P. pastoris Protein expression Proteins *** 
(Celik & Calık 2011) Yeasts Protein expression Proteins *** 
(Ward 2011) Fungi Protein expression Proteins *** 
(Wurm 2004) Mam Protein expression Biopharma * 
(Berkmen 2012) E. coli Protein expression Proteins with disulfide 
bonds 
* 
(de Marco 2009) E. coli Protein expression Proteins with disulfide 
bonds 
* 
(Schröder 2008) Eukaryotes Protein expression Biopharma ** 
(Fleissner & Dersch 
2010) 
Aspergillus Protein expression Enzymes ** 
(Lubertozzi & 
Keasling 2009) 
Aspergillus Native and 
heterologous PWs, 
protein expression 
Small molecules, 
proteins 
* 
(Vogl et al. 2013) P. pastoris Protein expression Biopharma * 
(Rosano & 
Ceccarelli 2014) 
E. coli Protein expression Proteins ** 
(Liu et al. 2013) Gram-positives Protein expression Proteins ** 
(Gasser et al. 2008) Bac, Yeasts, Fungi Protein expression Proteins ** 
*Abbreviations: Bac: Bacteria. Mam: Mammalian Cells.  1181 
 1182 
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 1183 
Figure 1. Ontology of different types of cellular engineering covered in this review. 1184 
1185 
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 1186 
Figure 2.  Engineering strategies for optimizing the production of native metabolites. Metabolites are 1187 
denoted S: Substrate. S2: Alternative substrate, X1-9: Pathway intermediates, P: Product of interest, BP: By-1188 
product. Generic engineering strategies are marked in blue and annotated as 1A-1I (described in the main 1189 
text).  1190 
1191 
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 1192 
Figure 3. Engineering strategies for heterologous expression of biosynthetic pathways in a (eukaryotic) 1193 
host cell. Metabolites are denoted S: Substrate, X1-6: Pathway intermediates, P: Product of interest, CS: Co-1194 
substrate, E1-10: Enzymes, FG: Functional group. The inserted heterologous pathway is marked in green. 1195 
Generic engineering strategies are boxed in blue and annotated as 2A-2F (described in the main text).  1196 
1197 
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 1198 
Figure 4. Overview of generic engineering strategies for expression of proteins in a (eukaryotic) host cell. 1199 
The inserted gene and its derived mRNA and polypeptide are marked in green. Generic engineering 1200 
strategies are marked in blue and annotated as 3A-3J (described in the main text). 1201 
 1202 
